image descriptionimage description

HUMIRA helps reduce pain, stiffness and swelling in children1,2

If your child is has been diagnosed with moderate to severe polyarticular juvenile idiopathic arthritis (JIA) and is still experiencing symptoms like joint pain, stiffness, and swelling, it may be time to see if HUMIRA can help

As the parent of a child with polyarticular juvenile idiopathic arthritis, you know how frustrating it can be when your child is still experiencing symptoms such as;

  • joint swelling (inflammation)
  • joint pain and stiffness, especially after sleeping
  • fatigue and tiredness
  • difficulty moving.

Is it time to consider another JIA treatment? Find out if HUMIRA could be right for your child

Treatment with other medicines may not be enough to relieve the symptoms, and HUMIRA may be an option.

The government medicine funding agency, PHARMAC, fully subsidises HUMIRA for your child’s JIA if they have not fully responded to other medicines prescribed by a specialist, and you meet other criteria required by PHARMAC. Your child’s specialist will discuss whether HUMIRA is right for your child, and whether your child may qualify for PHARMAC funded treatment.

HUMIRA is a biologic disease-modifying anti-rheumatic drug, also called a biologic DMARD, or simply ‘biologic’. HUMIRA works differently to conventional DMARDs because it works by identifying and blocking a specific source of inflammation that contributes to polyarticular juvenile idiopathic arthritis symptoms.

HUMIRA is only available on prescription for children four years of age and older. Talk to your child’s rheumatologist or specialist to see if HUMIRA is right for them.

HUMIRA helps reduce pain, stiffness and swelling in children1,2

HUMIRA is usually used with methotrexate, or alone, when methotrexate is no longer working well enough, or no longer appropriate.

HUMIRA may be an effective option for some children.

A clinical study showed you can expect fewer disease flares when treated with HUMIRA (both alone and in combination with methotrexate), compared to no HUMIRA treatment1. It was also shown you may expect around 7 out of 10 children on HUMIRA alone, and 9 out of 10 children on HUMIRA and methotrexate, to experience a reduction in symptoms after four months of treatment.1

Rheumatologists and other specialists may prescribe HUMIRA with or without methotrexate.

References:
# All experiences, possible outcomes or improvements are hypothetical and based on significant Quality Of Life (QOL) improvements as measured in the listed clinical studies. Use of these references does not imply endorsement or approval by any individual or the authors.

  1. Lovell,DJ et al. N Engl J Med 2008; 359:810-20
  2. Schmeling, H. et al. Arth Rheum 2014; 66:2580-89

NZ-HUM-0115 TAPS PP9594 Prepared May 2017

Learn how HUMIRA works

Watch this short video to get a better understanding of how HUMIRA targets and helps to block TNF.

How HUMIRA treatment works video transcript

Usually, your immune system defends your body from many of the things that can harm it. But when the system doesn’t work right, it can attack healthy tissues and organs. This is an autoimmune disease. One part of your immune system is a protein called TNF, which is produced naturally by the body’s immune system. But in certain autoimmune diseases, some people produce too much TNF. This often leads to inflammation. HUMIRA is a medication called a TNF blocker. It works by binding to TNF molecules and blocking them from attaching to and making cells behave in a way which leads to effects on health. In this way, HUMIRA helps reduce the damaging effects of excess TNF. Remember, although HUMIRA can’t stop your body’s overproduction of TNF it can reduce its effects.

The immune system can overproduce the TNF protein, which is one source of inflammation that contributes to the symptoms of juvenile idiopathic arthritis. HUMIRA targets and helps block TNF (a particular protein), reducing its inflammatory effects on the joints and the symptoms of joint pain, swelling, and stiffness.

Talk to your rheumatologist or other specialists about whether HUMIRA is right for treating your child’s polyarticular juvenile idiopathic arthritis (JIA)

References:
# All experiences, possible outcomes or improvements are hypothetical and based on significant Quality Of Life (QOL) improvements as measured in the listed clinical studies. Use of these references does not imply endorsement or approval by any individual or the authors.

  1. Lovell,DJ et al. N Engl J Med 2008; 359:810-20
  2. Schmeling, H. et al. Arth Rheum 2014; 66:2580-89

NZ-HUM-0115 TAPS PP9594 Prepared May 2017

Find out what to expect when your child starts treatment with HUMIRA for polyarticular juvenile idiopathic arthritis (JIA)

Based on clinical study results, you may expect HUMIRA (potentially in combination with other prescribed medications) to lead to improvements in your child’s symptoms by week sixteen, however it may be
sooner or take longer.1,2

Start out on the right path by learning how to take, or administer, HUMIRA correctly

For children who weigh between 15kg and 30kg, the recommended dose is 20mg every two weeks, and for children and adolescents who weigh 30kg or more, the recommended dose is 40mg every two weeks. Your child’s rheumatologist or other specialist will decide what dosage of HUMIRA is required, and how often the injection needs to be administered. Only administer as prescribed by them.

HUMIRA is given by injection just under the skin. HUMIRA is available in either a pre-filled single use syringe (10 mg, 20 mg and 40 mg), or pre-filled single-use auto-injector pen (40 mg) and all come pre-loaded with the exact dose of medicine inside, so it comes ready to inject and you can do it in your own home once trained. Your rheumatologist, specialist or nurse will be able to help you and be with you for your first injection, however before long you will be able to do it at home with your child, or if not, it can be given by a healthcare professional, another family member or friend, after they have been trained to give injections. Also, for people on HUMIRA in New Zealand you can join the AbbVie Care support programme with access to a nurse to help you.

Watch these short videos to get a better understanding of how to inject HUMIRA.

Pen video also available in the following languages:
Hindi    Simplified Chinese    Samoan    Tongan

NZ-IMM-0046

Syringe video also available in the following languages:    
Hindi    Simplified Chinese    Samoan    Tongan

NZ-IMM-0047

Storage and travelling with HUMIRA

Keep HUMIRA in the outer carton until it is time to use it. HUMIRA must be kept in the refrigerator (+2° C to +8° C) but don’t allow it to freeze. If you are travelling the HUMIRA pre-filled pen or pre-filled syringe may be stored at room temperature (below +25° C) for a maximum period of 14 days, but it must be protected from light. Once removed from the refrigerator for room temperature storage, the syringe or pen must be used within 14 days or discarded even if it is returned to the refrigerator. If additional syringes or pens are being carried, they should be refrigerated (kept between 2°C–8°C).

Join AbbVie Care to receive an ice pack and order a travel wallet through www.abbviecare.co.nz or call 0800 848 243.

When planning to travel overseas it is important that you:

  • talk to your doctor about travelling with HUMIRA
  • carry a letter from your doctor detailing what HUMIRA is, how much you will be taking, and stating that it is for your own personal use
  • leave HUMIRA in its original packaging so it is clearly labeled with your name and dosage instructions (if you are taking HUMIRA pens/syringes with you)


AbbVie Care Support Programme helps take care of you

AbbVie Care is available to you when you are taking HUMIRA. Support from AbbVie Care is designed to complement the care you receive from your specialist and clinic nurse.
AbbVie Care provides personalised support to meet each person’s needs. The aim is by working together people can achieve better outcomes with their health and quality of life.

It’s easy to ENROL

JOIN AbbVie Care to get the best out of your HUMIRA treatment

• Call 0800 848 243

How AbbVie Care supports you:

AbbVie Care Nurse

AbbVie Care Nurse Support

– Home visits or phone calls to help with injecting^
– Scheduled phone calls to provide information and support
– An 0800 number to call when you have a question

AbbvieCare Sharps Disposal Programme

Sharps Disposal Programme

– Delivery of sharps container to safely dispose of your HUMIRA pens and syringes
– Access to pharmacy disposal of your sharps container

AbbvieCare Travel Wallet

Travel Wallet

– Designed to make travelling with HUMIRA safer and easier

Abbvie_Care_Welcome_Kit

Welcome Kit

– Information on all you need to know to get the best out of AbbVie Care
– Ice pack to assist with injecting


References:
All experiences, possible outcomes or improvements are hypothetical and based on significant Quality Of Life (QOL) improvements as measured in the listed clinical studies. Use of these references does not imply endorsement or approval by any individual or the authors.
^Home visits do not cover all of New Zealand. Your AbbVie Care Nurse will be able to discuss this with you when you join AbbVie Care.

  1. Lovell,DJ et al. N Engl J Med 2008; 359:810-20
  2. Schmeling, H. et al. Arth Rheum 2014; 66:2580-89

NZ-HUM-0115 TAPS PP9594 Prepared May 2017

The following resources have been compiled to help you get support outside the HUMIRA AbbVie Care programme. We hope you find them useful.

Arthritis New Zealandlogo_Arthritis-New-Zealand

A national voluntary organisation which represents the interests of those with arthritis. Information on the condition and its treatment.

www.arthritis.org.nz/information/children-with-arthritis/

Health Navigator New Zealand

The Health Navigator website provides one place for New Zealanders to find reliable and trustworthy health information and self-care resources. It focuses on promoting clear, consistent messages that enable users to get the information they need at the time they need it.

www.healthnavigator.org.nz/health-a-z/a/arthritis-in-children/ 

 Arthritis Australia

An Australian national organisation which represents the interests of those with arthritis. Information on the condition and its treatment.

www.arthritisaustralia.com.au/index.php/arthritis-information/kids-get-arthritis-too.html

Arthritis United Kingdom

The United Kingdom’s national organisation which represents the interests of those with arthritis. Information on the condition and its treatment.

www.arthritiscare.org.uk

Arthritis Foundation USA

An American national organisation which represents the interests of those with arthritis. Information on the condition and its treatment.

www.arthritis.org/about-arthritis/types/juvenile-idiopathic-arthritis-jia/

New Zealand Rheumatology Association

The New Zealand Rheumatology Association (NZRA) is the organisation that represents the rheumatologists of New Zealand.

www.rheumatology.org.nz

Use this link to search for Rheumatologists. You can type in a city, region or surname.
www.rheumatology.org.nz/home/member_list/

Australian Rheumatology Association

The ARA is an association of rheumatologists in Australia that is a specialty society of the Royal Australasian College of Physicians (RACP).

www.rheumatology.org.au

Information sheets are available via the Arthritis Australia website at the following direct link:

www.arthritisaustralia.com.au/index.php/arthritis-information/information-sheets.html

American College of Rheumatology

The American College of Rheumatology (ACR) is an ethically-driven, professional membership organization committed to improving the care of patients with rheumatic disease and advancing the rheumatology subspecialty.

www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Juvenile-Arthritis

References:
# All experiences, possible outcomes or improvements are hypothetical and based on significant Quality Of Life (QOL) improvements as measured in the listed clinical studies. Use of these references does not imply endorsement or approval by any individual or the authors.

  1. Lovell,DJ et al. N Engl J Med 2008; 359:810-20
  2. Schmeling, H. et al. Arth Rheum 2014; 66:2580-89

NZ-HUM-0115 TAPS PP9594 Prepared May 2017